enGene Q2 loss $25.8M ($0.51/shr); cash $251.5M; LEGEND study on track

enGene Therapeutics Inc.

2025-Q2 EPS reported $0.99 vs consensus -$0.51 ▲ beat (+294.8%)

Net loss $25.8M ($0.51/shr) vs $15.0M ($0.38) YoY; operating expenses $27.1M (up 57%).
Cash and marketable securities $251.5M expected to fund operations into 2027.
LEGEND pivotal cohort enrollment on track; BLA filing for detalimogene planned mid-2026.
EMA indicates data could support Conditional Marketing Authorization for BCG-unresponsive NMIBC.
Amy Pott appointed Chief Global Commercialization Officer effective May 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.